PubMed Health⌕ Search

Biomedical subjects

S Mattsson

Publications and source records attributed to S Mattsson.

At least 19 recordsLinked to original sources
PubMed1992

Effective dose from radiopharmaceuticals.

The effective dose, as defined by the International Commission on Radiological Protection (ICRP 1991), provides a possibility of expressing the radiation risk to patients undergoing different radiodiagnostic procedures by means of a single figure. This has been obtained by introducing organ or tissue weighting factors reflecting the radiation sensitivity of the organs. Such weighting factors were first published by the ICRP in publication 26 (1977), and have now been revised in publication 60 (1991). The effective dose for almost all radiopharmaceuticals in clinical use has been recalculated using the new weighting factors from ICRP 60 (1991) and compared with results from former calculations. A slight decrease in the numerical value for the effective dose has been observed, on average 11%. However, this does not correspond to a decrease in the estimated risk from the irradiation, since this has been re-evaluated and found to be higher than earlier believed (NAS 1990; ICRP 1991).

Humans↗
PubMed1992

Calibration of bone mineral and heavy metal measurements using doped wall-less gel phantoms of arbitrary form.

Cylindrical gel phantoms of 2% agarose concentration were used as wall-less phantoms of arbitrary shape for calibration purposes in non-destructive measurements of bone mineral and heavy metal concentration using XRF. The counts of the coherently and incoherently scattered photons with no sample present should be subtracted as "background" to get a linear relationship between the ratio of the coherently and incoherently scattered photons and the bone mineral concentration for phantoms of arbitrary diameters.

Bone Density↗
PubMed1992

Comparison of the biodistribution of 75Se- and 131I-labelled monoclonal antibodies in nude mice.

A monoclonal antibody, C-215, against colon cancer, was internally labelled with [75Se]methionine. The biodistribution was studied in tumour-bearing nude mice and compared with the biodistribution of [131I]C-215. The tissue uptake was divided into three parts: antibody bound to the antigen, antibody in the extracellular space and uptake of the released radionuclide. [75Se]C-215 showed a greater amount of antigen-bound antibody in the tumour, but also a greater unspecific uptake both in tumour and normal tissue.

Animals↗
PubMed1992

Quantitative bone scintigraphy and 24-hour whole-body counting of 99mTc-methylene diphosphonate in patients with prostatic carcinoma.

Thirty-four patients with prostatic carcinoma were studied with quantitative bone scintigraphy and whole-body counting (WBC) 1 and 24 h after injection of 99mTc-MDP before as well as two weeks and two months after orchiectomy. Thirteen of the patients had normal bone scintigrams and WBR at the three different investigations; 21 had skeletal metastases. The latter showed throughout the study higher local gamma camera count rates as well as WBR values than the patients with normal scintigrams. In these patients a "flare phenomenon", with an increase in count rate two weeks after orchiectomy followed by a decrease two months post-operatively, was seen with quantitative bone scintigraphy but not with WBC. However, WBC may be a valuable method indicating the total extent of skeletal metastases in the body, while quantitative bone scintigraphy is more accurate in the interpretation of individual skeletal metastases.

Aged↗
PubMed1991

Absorbed dose to technicians due to induced activity in linear accelerators for radiation therapy.

Absorbed dose to the trunk and to the hands of technicians working with accelerators for radiotherapy have been measured with TL dosimeters for seven different accelerators. The contribution from induced activity in the accelerator and from radiation transmitted through the walls of the treatment room have been estimated separately. The total annual absorbed dose to the trunk and to the hands have been estimated to be 2 mGy, of which the induced activity contributes one-third (0.7 mGy). The exposure of the technicians was found to be dominated by radiation penetrating the walls of the treatment room. For one accelerator the absorbed dose rate in the treatment room was measured continuously between 0.5 min and 48 h after end of treatment. Immediately after irradiation with high-energy photons the radiation is dominated by 28Al and 62Cu T1/2 = 2.3 and 9.7 min respectively) and later by radionuclides with longer half-lives, 187W and 57Ni (T1/2 = 24 and 36 h respectively). Due to these radionuclides the radioactivity in the accelerator will build up and the technicians will therefore be irradiated every time they enter the treatment room and not only directly after a treatment with high-energy photons.

Electrons↗
PubMed1991

Relationship between 99Tcm-MDP uptake and bone mineral density in patients with prostatic carcinoma.

Seventeen men with prostatic carcinoma were investigated with quantitative bone scintigraphy and quantitative computed X-ray tomography before orchiectomy and up to 6 months after this operation. The uptake of 99Tcm-labelled methylene disphosphonate (99Tcm-MDP) and bone mineral density (BMD) were determined for each vertebra from Th10 to L4. Ten patients had normal scintigrams. No change in MDP uptake or BMD was seen after 6 months in these patients. Of the seven patients with abnormal scintigrams, one patient had a clinical sign of progression with an increase in both MDP uptake and BMD. The remaining six patients showed stable or improved clinical status. For their abnormal vertebrae a decrease in MDP uptake was seen, while BMD varied in different ways after 6 months. For the normal vertebrae in these patients with metastatic involvement, no change in MDP uptake was seen. However, the BMD values showed a decrease, indicating a generalized increase in bone resorption at sites distant from the metastases.

Aged↗
PubMed1991

Kinetics of lead in bone and blood after end of occupational exposure.

In 14 retired lead workers, followed for over 18 years after end of exposure, repeated analyses of lead levels in finger bone by an in vivo X-ray fluorescence method revealed a decrease of lead concentration. The data were analysed using an exponential retention model. For the whole group the biological half-time was 16 (asymptotic 95% confidence interval, CI 12,23) years. The median of the estimated bone lead levels at the end of exposure was 85 micrograms.g-1 above the "background" (3 micrograms.g-1). A simultaneous follow-up of blood lead levels displayed a decrease, which could be described by a tri-exponential retention model with group half-times of 34 (CI 29,41) days, 1.2 (CI 0.9,1.8) years, and 13 (CI 10,18) years, respectively. The median of the estimated blood lead levels at the end of exposure for the three components were 0.49, 0.61, and 1.1 mumol.l-1 above the "background" (0.38-0.56 mumol.l-1), respectively. The well-documented decrease of lead exposure in the general population over the years, urged the use of a decreasing "background" of blood lead during the time of the study. The slowest of the three components represented the skeleton (probably mainly cortical bone), as did mainly probably also the intermediate one (trabecular bone). The data show the rather slow turnover of lead in the skeleton, the usefulnes of in vivo skeletal lead measurements as a long-term exposure index, and the importance of bone as a source of "endogenous" lead exposure.

Adult↗
PubMed1991

Uptake and retention of platinum in patients undergoing cisplatin therapy.

Results of in vivo measurements of the platinum concentration in kidneys and tumours of patients treated with cisplatin for testicular carcinoma, head and neck tumours and brain tumours are presented. The measurements were performed with an x-ray fluorescence technique. Our earlier studies have shown that maximum platinum levels in kidneys were reached 3-4 h after an intravenous injection of cisplatin. The present study showed that, at that time, the ratio between the concentration of platinum in kidney and in blood serum was 22 +/- 7 (+/- 1 S.D.). Between 24 and 72 h after administration this ratio was 10 +/- 3, as shown in another group of patients. Measurements of platinum concentration in brain tumours showed varying maximum uptake, between 14 and 40 micrograms/g, 5-15 h after administration. There was an indication that radiotherapy may increase the uptake of cisplatin in normal brain tissue. The technique described can be used for further studies of the platinum concentration in tumours and risk organs in connection with cisplatin therapy. Such studies are needed to find out how to improve the therapeutic effects and lower the toxic ones.

Adolescent↗
PubMed1991

Comparison of seven iodine-labelled monoclonal antibodies in nude mice with human colon carcinoma xenografts.

The biokinetics of seven 131I-labelled monoclonal antibodies (MAbs), directed against human colon carcinoma and one 125I-labelled unspecific MAb have been examined. The study in nude mice, carrying human colon carcinoma, was intended to be a step in the selection of the most suitable antibody for clinical scintigraphy. The biological half-life in blood was found to be between 1.3 and 7.4 days for the different MAbs. Chromatography of plasma samples showed that the radioiodine was mainly bound to IgG-sized molecules. The (normal tissue)/blood ratios were similar for all the MAbs. The tumour/blood ratio was 0.41 for the unspecific MAb and 0.49-1.1 for the specific MAbs, and the tumour/muscle ratio was between 3.2 and 6.8 for the specific MAbs 6 days after injection. For one MAb tumour/blood and tumour/muscle ratios were 3.9 and 9.8 respectively 9 days after injection. Localization indices were at their highest 2.6 6 days after injection. For at least two of the monoclonal antibodies the tumour/blood and tumour/muscle ratios found are high enough to justify clinical trials regarding their usefulness for scintigraphy of colon cancer in man.

Adenocarcinoma↗
PubMed1991

Additional information from quantitative 24-hour 99mTc-MDP bone scintigraphy in patients with prostatic carcinoma.

Quantitative bone scintigraphy was performed at 4 and 24 h after injection of 99mTc-MDP. The lower thoracic and all the lumbar vertebrae were recorded in 37 patients with prostatic carcinoma before orchiectomy as well as two weeks, two and six months postoperatively. Fourteen patients had normal bone scintigrams. By means of the measured variation in the count rate between normal vertebrae, the criterion for a vertebra to be considered as abnormal was determined using the 4 h-uptake values. For patients with normal scintigrams the count rate at 24 h was below the 4 h level and the mean 24 h/4 h ratio was determined to be 0.85 +/- 0.09 (1 SD). Normal vertebrae in patients with skeletal metastases had only slightly lower count rate values at 24 h than at 4 h. Abnormal vertebrae showed a higher count rate at 24 h, especially two weeks postoperatively, while a tendency towards lower values than at 4 h was seen after 6 months. If the 24 h/4 h ratio is used as an extra criterion to the count rate at 4 h, the vertebrae will be more accurately defined as normal or abnormal.

Aged↗
PubMed1990

Dynamic quantitative bone scintigraphy in patients with prostatic carcinoma treated by orchiectomy.

Dynamic quantitative bone scintigraphy was performed on 31 men with prostatic carcinoma before orchiectomy as well as 2 weeks, 2 and 6 months postoperatively. After injection of technetium methylene diphosphonate Tc 99m (99mTc-MDP) the count rate was recorded as serial images over the lower thoracic and all the lumbar vertebrae from 1 to 240 min post-injection. Thirteen men had normal bone scintigrams with no changes in 99mTc-MDP content at the four different investigation times. Eighteen men had skeletal metastases. Throughout the study half of the abnormal vertebrae in these patients showed an abnormal count rate after only 6 min post-injection. After 1 h it was possible in almost all abnormal vertebrae to predict abnormal bone uptake. In response to therapy a "flare phenomenon" with an increase in count rate was seen 2 weeks after orchiectomy followed by a decrease 2 months postoperatively in most of the abnormal vertebrae. The count rate decreased even below the pre-operative level after 6 months. Also, the normal vertebrae in the patients with skeletal metastases showed a tendency towards the flare phenomenon, which was not seen in patients with normal bone scintigrams.

Aged↗
PubMed1990

MR imaging of absorbed dose distributions for radiotherapy using ferrous sulphate gels.

The measurement of absorbed dose distributions using dosemeter gel and magnetic resonance imaging (MRI) in a standard geometry has been investigated. Absorbed depth-dose curves and profiles measured with this new technique show good agreement with corresponding measurements using diodes. This was proven in a 60Co beam as well as an electron beam. The dosemeter gel is made of agarose and ferrous sulphate solution. The dose response is linear (r = 0.9996) in the investigated dose interval, 0-40 Gy. The sensitivity is a factor of about six higher compared to ordinary ferrous sulphate solution, known as 'Fricke'. This is a true 3D dose measurement technique which will have a number of applications in radiation therapy, since it is possible to mould the gel to arbitrary geometries, mix different radiation qualities and integrate the absorbed dose from different kinds of fields.

Dose-Response Relationship, Radiation↗
PubMed1990

Relationship between kerma and treatment volume in intracavitary radiation therapy.

Data on 200 patients with carcinoma of the uterine cervix irradiated with afterloading brachytherapy using various high dose rate source configurations have been evaluated with respect to the total reference air kerma and the treatment volume as well as other volumes of interest. The experimental results showed good correlation between kerma and volume, and have also been discussed theoretically for the single-source, double-source and triple-source configurations. The possibility of using the demonstrated kerma-volume relationships for simple estimation of volumes enables us to select the appropriate treatment plan for the individual patient and to evaluate the results of the treatment.

Adsorption↗
PubMed1989

Ferrous sulphate gels for determination of absorbed dose distributions using MRI technique: basic studies.

Two gels have been found to be suitable to load with ferrous sulphate solution. In these soft tissue equivalent phantoms, the absorbed dose distribution can be measured after irradiation in clinically used MR imaging equipment. The present studies were carried out using a 0.25 T NMR analyser without imaging properties. A ferrous sulphate solution, 0.05 M with respect to sulphuric acid, can be gelled with 4% gelatin to give a dosemeter which has a response which is linearly correlated (r = 0.998) with the absorbed dose in the interval 0-40 Gy. Ferrous sulphate solution can also be gelled with 1% agarose, but this gel has to be purged with oxygen to obtain a linear relationship (r = 0.997) in the same absorbed dose interval. The ferrous sulphate loaded gels have a sensitivity which is a factor of 2.2 or 4.0 times higher for gelatin and agarose, respectively, than the ordinary dosemeter solution. Because the standard deviation of background measurements is higher for the gels than for the dosemeter solution, the minimum detectable absorbed dose is about the same, or 1.0 Gy, for the two gels and the dosemeter solution. The sensitivity of the ferrous sulphate loaded gels shows no dependence on dose rate if the mean dose rate and the absorbed dose per pulse are within the limits normally used by accelerators for radiotherapy.

Ferrous Compounds↗
PubMed1989

In vivo measurements of bone lead--a comparison of two x-ray fluorescence techniques used at three different bone sites.

In vivo bone lead measurements have been made on a group of about 120 people, most of whom were lead exposed workers. Two different x-ray fluorescence (XRF) techniques were used to make measurements at three bone sites. Finger lead was measured using 57Co sources, and lead measurements were made in both tibia and calcaneus with a technique based on 109Cd sources. The results of the bone lead measurements correlated strongly with each other and with the index of cumulative exposure, thus confirming the value and reliability of these in vivo measurements as a tool in the study of chronic lead exposure. Measurement precision, +/- 1 standard deviation, was highest for tibia +/- 7.4 micrograms (g bone mineral)-1, +/- 16.6 micrograms (g bone mineral)-1 for the calcaneus and lowest for phalangeal lead +/- 25.0 micrograms (g bone mineral)-1. Maximum absorbed doses to the skin were comparable for all three measurements (1-3 mGy). The mean whole body dose equivalents were all low, but that for the finger measurement, 0.1 microSv, was significantly less than for the calcaneus and tibia measurements 3-5 microSv.

Bone and Bones↗
PubMed1989

Kinetics of radioiodinated monoclonal antibodies in the rat. Influence of tumour growth and reticuloendothelial system host modulation.

This experimental study in rats examines the influence of tumour growth and RES function modulation on the kinetics of iodinated MAb IgG1 C241. The study was designed to investigate unspecific accumulation in liver and blood. C241 is raised against human colon adenocarcinoma COLO 205 and reacts with SiLea tumour-associated antigen, also known as tumour-associated antigen 19-9. In 26 rats, 2 micrograms 125I MAb C241 (lodobead labelling method) was given i.v. Blood, organ and tumour content was measured at 0.5, 24, 72 and 144 h. In 61 rats, 10 micrograms 131I MAb C241 (lodogen labelling method) was given i.v. The rats were divided into a non-tumour and a tumour-bearing group and subjected to RES function modulation with Zymosan stimulation or methyl palmitate depression. A syngeneic nitrosoguanidine-induced colonic carcinoma--mean 11 g--was growing in back subcutaneous tissue and hind leg musculature. Serum content of tumour-associated antigen was not found on IRMA testing and tumour content of SiLea ganglioside antigen was found only on lipid binding phase assay. The half-time in blood of iodinated MAb C241 was three days. In-vivo release of iodine was tested by plasma separation on a gel column. More than 90% of the iodine was in the IgG fraction. The activity distribution was almost in equilibrium after 24 h. A tumour/blood activity concentration ratio of 0.5 and liver/blood ratio of 0.3 remained at 72 h and 144 h. Radionuclide accumulation was equally low in the macrophage-rich liver and the kidneys. Tumour-bearing animals had significantly lower blood content (0.37 versus 0.99% g-1) and liver content (0.09 versus 0.31% g-1) at 144 h than non-tumour-bearing rats. The whole body content at 144 h was also lower (24% versus 35% of administered activity) (p = 0.10). Modulation of RES function had no significant influence on the whole body, blood or liver content of 131I MAb C241 activity in non-tumour-bearing animals. In tumour-bearing animals, RES stimulation with Zymosan increased the whole body, liver and blood content of 131I activity. The two tested methods of iodination gave similar results.

Adenocarcinoma↗